Trial Profile
Randomized evaluation of short-term rifalazil treatment on carotid atherosclerosis and intima media thickness.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Rifalazil (Primary)
- Indications Atherosclerosis; Chlamydial infections
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms RESTORE-IT
- Sponsors ActivBiotics
- 24 Oct 2007 Status change from recruiting to in progress, in accordance with media release 9081447.
- 22 Feb 2007 New trial record.